India and USA team up on key pharma inputs to slash China reliance

As part of an initiative to reduce global dependence on China for the supply of crucial pharmaceutical and active pharmaceutical ingredient (API) requirements, India and the USA have agreed to collaborate on the development of APIs and vaccine materials.

USA President Joe Biden recently rolled out the red carpet for Indian Prime Minister Narendra Modi's third state visit during his presidency. India has decided to leverage the health diplomacy it initiated with the USA during the COVID-19 pandemic, and take it to the next level.

Welcoming the opportunity for deeper collaboration to secure pharmaceutical supply chains, an agreement was signed to "secure, de-risk, and strengthen" pharma supply chains, with a focus on APIs, key starting materials (KSMs), and key vaccine input materials. The aim is to showcase a "secure, resilient, reliable" and growing pharmaceutical supply chain as a model for the world.